BANZATO, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.519
AS - Asia 2.782
EU - Europa 1.242
SA - Sud America 505
AF - Africa 475
OC - Oceania 37
Continente sconosciuto - Info sul continente non disponibili 26
Totale 10.586
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.277
SG - Singapore 850
CN - Cina 595
VN - Vietnam 428
BR - Brasile 318
IT - Italia 221
HK - Hong Kong 211
DE - Germania 140
BD - Bangladesh 111
FI - Finlandia 101
FR - Francia 95
NL - Olanda 75
GB - Regno Unito 65
SE - Svezia 65
IN - India 63
RU - Federazione Russa 52
PL - Polonia 46
TR - Turchia 46
AR - Argentina 45
CA - Canada 45
IQ - Iraq 44
UA - Ucraina 36
JP - Giappone 32
EC - Ecuador 31
CI - Costa d'Avorio 28
MA - Marocco 28
KR - Corea 26
SA - Arabia Saudita 26
ZA - Sudafrica 26
CO - Colombia 25
PK - Pakistan 24
PH - Filippine 23
VE - Venezuela 22
AT - Austria 21
JM - Giamaica 21
ID - Indonesia 20
UZ - Uzbekistan 20
AL - Albania 19
BE - Belgio 19
IE - Irlanda 19
MX - Messico 19
GA - Gabon 18
MW - Malawi 18
MY - Malesia 18
TN - Tunisia 18
NP - Nepal 17
RO - Romania 17
AE - Emirati Arabi Uniti 16
AO - Angola 16
GR - Grecia 16
PE - Perù 16
PT - Portogallo 16
TZ - Tanzania 16
BG - Bulgaria 15
CR - Costa Rica 15
EG - Egitto 15
RS - Serbia 15
ES - Italia 14
PY - Paraguay 14
TW - Taiwan 14
AM - Armenia 13
BS - Bahamas 13
CW - ???statistics.table.value.countryCode.CW??? 13
GH - Ghana 13
HR - Croazia 13
HU - Ungheria 13
KZ - Kazakistan 13
LA - Repubblica Popolare Democratica del Laos 13
ML - Mali 13
MR - Mauritania 13
SI - Slovenia 13
CL - Cile 12
DJ - Gibuti 12
DO - Repubblica Dominicana 12
DZ - Algeria 12
ET - Etiopia 12
GN - Guinea 12
HN - Honduras 12
KG - Kirghizistan 12
LB - Libano 12
LV - Lettonia 12
ME - Montenegro 12
TT - Trinidad e Tobago 12
BJ - Benin 11
CM - Camerun 11
CU - Cuba 11
CZ - Repubblica Ceca 11
DK - Danimarca 11
KE - Kenya 11
LY - Libia 11
MD - Moldavia 11
PA - Panama 11
SD - Sudan 11
SO - Somalia 11
TJ - Tagikistan 11
YE - Yemen 11
ZW - Zimbabwe 11
BW - Botswana 10
IR - Iran 10
IS - Islanda 10
Totale 10.153
Salva come PNG Salva come JPEG
Città #
Ashburn 690
Fairfield 635
Singapore 536
San Jose 534
Chandler 361
Woodbridge 351
Houston 332
Ann Arbor 260
Seattle 220
Cambridge 219
Wilmington 188
Hong Kong 183
Beijing 154
Ho Chi Minh City 109
Jacksonville 93
Hanoi 89
Boardman 79
San Diego 77
Dong Ket 75
Princeton 75
Santa Clara 68
Los Angeles 59
New York 56
Lauterbourg 47
Helsinki 45
Roxbury 44
Des Moines 41
Nanjing 41
Medford 40
Munich 36
Frankfurt am Main 30
Bytom 28
Milan 28
Abidjan 27
Guangzhou 24
São Paulo 24
Dallas 23
Padova 23
Tokyo 23
Baghdad 22
Montreal 19
Chicago 18
Libreville 18
Buffalo 17
Kingston 17
Nanchang 17
Orem 17
Da Nang 16
Luanda 16
Rome 16
Tashkent 16
Dublin 15
Dar es Salaam 14
Shenyang 14
Bamako 13
Belo Horizonte 13
Hebei 13
Johannesburg 13
London 13
Nassau 13
San José 13
Seoul 13
Biên Hòa 12
Brooklyn 12
Conakry 12
Nouakchott 12
Vienna 12
Vientiane 12
Willemstad 12
Addis Ababa 11
Atlanta 11
Bishkek 11
Guayaquil 11
Harare 11
Istanbul 11
Nuremberg 11
Podgorica 11
Quito 11
Yerevan 11
Amman 10
Cotonou 10
Council Bluffs 10
Djibouti 10
Haiphong 10
Hefei 10
Jeddah 10
Lilongwe 10
Nairobi 10
Panama City 10
Redondo Beach 10
Rio de Janeiro 10
Shanghai 10
Tianjin 10
Tripoli 10
Accra 9
Athens 9
Baku 9
Casablanca 9
Dakar 9
Dushanbe 9
Totale 6.721
Salva come PNG Salva come JPEG
Nome #
A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. 298
Laboratory testing for antiphospholipid syndrome 287
(188)Rhenium-induced cell death and apoptosis in a panel of tumor cell lines 282
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 281
Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate 273
Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles 261
Bioavailability of Tc-99m-Ha-paclitaxel complex [Tc-99m-ONCOFID-P] in mice using four different administration routes 260
A paclitaxel-hyaluronan bioconjugate exerts a high in vivo therapeutic activity against ovarian cancer 258
APS - Diagnostics and challenges for the future 250
The Paradox of the Lupus Anticoagulant: History and Perspectives 250
Diagnosis and therapy of antiphospholipid syndrome 245
Laboratory Diagnostics of Antiphospholipid Syndrome 245
Biokinetic and dosimetric studies of Re-188-hyaluronic acid: a new radiopharmaceutical for treatment of hepatocellular carcinoma 239
Lupus anticoagulant testing: Diluted Russell Viper Venom Time (dRVVT) 230
Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review 228
Circulating β2 glycoprotein I-IgG anti-β2 glycoprotein I immunocomplexes in patients with definite Antiphospholipid Syndrome. 227
Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk 226
A YAP camera for the biodistribution of Re-188 conjugated with Hyaluronic-Acid in "in vivo" systems 222
Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant 221
Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial 218
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. 212
β2-Glycoprotein I Binds to Thrombin and Selectively Inhibits the Enzyme Procoagulant Functions 211
Antiphospholipid syndrome: critical analysis of the diagnostic path 209
Confirmation of the initial antiphospholipid antibody positivity depends on antiphospholipid antibody profile 208
The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis 198
HYTAD1-p20: A new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer 197
The role of platelets in antiphospholipid syndrome 195
Interpretation of laboratory data and need for reference laboratories. 194
Hyaluronan as carrier of carboranes for tumor targeting in boron neutron capture therapy 194
Correct laboratory approach to APS diagnosis and monitoring 193
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. 186
Novel types of carborane-carrier hyaluronan derivatives via "click chemistry". 185
Detection of lupus anticoagulant in the era of direct oral anticoagulants 180
Chemical Synthesis and Characterization of Wild-type and Biotinylated N-terminal Domain 1-64 of Beta2-glycoprotein I 173
Secondary prevention in thrombotic antiphospholipid syndrome. 171
Radiopharmacokinetic and dosimetric studies of Re-188-HA: comparison with Re-188-HDD/lipiodol 166
Hydrosoluble, Metabolically Fragile Bioconjugates by Coupling Tetrabutylammonium Hyaluronan with 2′ Paclitaxel-4-Bromobutyrate: Synthesis and Antitumor Properties 164
Clinical Relevance of β2-Glycoprotein-I Plasma Levels in Antiphospholipid Syndrome (APS) 163
Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome. 163
PN2S-PEG-BIOMOLECULE DERIVATIVES LABELED WITH TECHNETIUM-99m IN ABSENCE OF AN EXTERNAL REDUCING AGENT 159
Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study 158
Paclitaxel-hyaluronan hydrosoluble bioconjugate: Mechanism of action in human bladder cancer cell lines. 156
Identifying novel thrombin interactions: Alpha-synuclein binds to thrombin exosites and inhibits thrombin-mediated platelet aggregation 156
Preliminary data on the evaluation of Rhenium-188 in radiotherapy application Hyaluronic Acid as vector for liver neoplasies and DNA damage induced by 188Re in vitro systems 154
Beta 2 glycoprotein I selectively inhibits the procoagulant function of thrombin: a novel physiologic anticoagulant mechanism in haemostasis 146
Standardization of lupus anticoagulant. Feasibility study of a calibration model to minimize between-method variability 142
The challenges of lupus anticoagulants 139
Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA) 136
A mouse model of liver metastasis 134
What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? 133
Risk-based secondary prevention of obstetric antiphospholipid syndrome. 125
Radiopharmacokinetic and dosimetric studies of 188Re-HA: comparation with 188Re-HHD/lipiodol 120
Effect of anti beta2-glycoprotein I Lupus Anticoagulant antibodies on clotting time in the presence of human umbilical vein endothelial cells 105
Novel thrombin interactions: alpha-synuclein binds thrombin exosites and inhibits thrombin-mediated platelet aggregation 103
Totale 10.629
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.172
article - articoli 28.859
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.031
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022775 19 95 102 71 13 47 36 86 30 13 73 190
2022/2023642 129 83 10 73 106 78 0 52 67 7 28 9
2023/2024340 4 59 38 19 27 65 24 51 7 1 27 18
2024/20251.260 8 69 79 52 164 38 108 116 90 35 194 307
2025/20264.807 224 424 575 730 465 208 612 398 545 285 162 179
2026/2027118 118 0 0 0 0 0 0 0 0 0 0 0
Totale 10.629